Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetu...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Even, Aniek J.G., Hamming-Vrieze, Olga, van Elmpt, Wouter, Winnepenninckx, Véronique J.L., Heukelom, Jolien, Tesselaar, Margot E.T., Vogel, Wouter V., Hoeben, Ann, Zegers, Catharina M.L., Vugts, Daniëlle J., van Dongen, Guus A.M.S., Bartelink, Harry, Mottaghy, Felix M., Hoebers, Frank, Lambin, Philippe
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354801/
https://ncbi.nlm.nih.gov/pubmed/27965472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13910
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items